(Q34034492)

30 July 2017

title

A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression (English)

1 reference

treatment-resistant depression

30 July 2017

1 reference

ChEBI release 2020-05-28

ChEBI ID

40009

1 reference

6

Daniel C Javitt

1 reference

30 July 2017

Uriel Heresco-Levy

1

1 reference

30 July 2017

Genia Gelfin

2

1 reference

30 July 2017

Boaz Bloch

3

1 reference

30 July 2017

Raz Levin

4

1 reference

30 July 2017

Shani Edelman

5

1 reference

30 July 2017

Ilana Kremer

7

1 reference

30 July 2017

publication date

17 September 2012

1 reference

The International Journal of Neuropsychopharmacology

30 July 2017

published in

1 reference

30 July 2017

volume

16

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

501-506

1 reference

Glutamate-based antidepressants: 20 years on.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

Cyloserine as an antidepressant agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

inferred from DOI database lookup

7 January 2021

based on heuristic

Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

inferred from DOI database lookup

7 January 2021

based on heuristic

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000910

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S1461145712000910

1 reference

30 July 2017

1 reference